前列腺腺癌（PRAD）由遗传和表观遗传因素驱动，是一种影响全世界男性的常见恶性肿瘤。我们的目的是鉴定和表征 PRAD 中差异表达的表观遗传相关基因 (ERG)，并研究它们在疾病进展和预后中的潜在作用。我们使用来自癌症基因组图谱 (TCGA) 和基因表达综合 (GEO) 的 PRAD 样本来识别与预后相关的 ERG。通过共识聚类鉴定出 13 个具有两种不同表达谱的 ERG。基因集变异分析强调了通路活性的差异，特别是 Hedgehog 和 Notch 通路。较高的表观遗传评分与良好的预后和改善的免疫治疗反应相关。实验验证强调了 CBX3 和 KAT2A 的重要性，表明它们在 PRAD 中的关键作用。这项研究提供了对表观遗传评分方法的重要见解，并提出了一种有前途的预后工具，其中 CBX3 和 KAT2A 是关键参与者。这些发现为治疗 PRAD 的针对性和个性化干预措施铺平了道路。© 2024 作者。

Prostate adenocarcinoma (PRAD), driven by both genetic and epigenetic factors, is a common malignancy that affects men worldwide. We aimed to identify and characterize differentially expressed epigenetic-related genes (ERGs) in PRAD and investigate their potential roles in disease progression and prognosis. We used PRAD samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to identify prognosis-associated ERGs. Thirteen ERGs with two distinct expression profiles were identified through consensus clustering. Gene set variation analysis highlighted differences in pathway activities, particularly in the Hedgehog and Notch pathways. Higher epigenetic scores correlated with favorable prognosis and improved immunotherapeutic response. Experimental validation underscored the importance of CBX3 and KAT2A, suggesting their pivotal roles in PRAD. This study provides crucial insights into the epigenetic scoring approach and presents a promising prognostic tool, with CBX3 and KAT2A as key players. These findings pave the way for targeted and personalized interventions for the treatment of PRAD.© 2024 The Authors.